ErbB2 pY -1248 as a predictive biomarker for Parkinson's disease based on research with RPPA technology and in vivo verification.

Meng JinRuidie ShiDaili GaoBaokun WangNing LiXia LiAttila SikKechun LiuXiujun Zhang

Published in: CNS neuroscience & therapeutics (2023)

is a predictive biomarker of PD by using RPPA technology and in vivo verification. It offers a new perspective on PD diagnosing and treatment, which will be essential in identifying individuals at risk of PD. In addition, this study provides new ideas for digging into biomarkers of other neurodegenerative diseases.

Keyphrases

combination therapy
replacement therapy
monte carlo